Mazor Robotics reported five Renaissance robotic spine surgery systems during the third quarter.
The company will release their financial report later this month, but provided insight into who is purchasing their robotic systems for brain and spine surgery as of Sept. 30. The company launched the brain surgery module for the Renaissance robotic spine surgery system earlier this year.
One of the systems sold last quarter included both the brain and spine module. The company also sold two brain module upgrades to existing Renaissance users. All systems and modules sold in the quarter were installed and upgraded before the quarter ended.
Mazor now has 44 systems in the United States, including systems in new major metropolitan areas such as San Francisco and Detroit.
"We also installed systems in our developed clusters, penetrating deeper into these markets where we continue to see significant growth opportunities," said company CEO Ori Hadomi. "Furthermore, we are very encouraged from the initial interest from current and prospective customers of the newly launched brain application."
There were several key events for the company in the third quarter, including:
• Gaining China Food and Drug Administration approval for the Renaissance system
• George Martin, MD, performed his 200th spine surgery with the Renaissance system at Foundation Surgical Hospital of El Paso
The second quarter was disappointing for Mazor, only selling two Renaissance robotic spine surgery systems in the United States. Two others were purchased in Asia, including the first system in Hong Kong. The company reported a net loss at $3.7 million on a non-GAAP basis. Net revenue dropped to $4.5 million in the second quarter of 2014, compared with $6.2 million for the second quarter of 2013.